RAND Europe are pleased to submit evidence to this call for evidence related to the EU Biotech Act. Our submission covers six key themes: governance, workforce development, data and AI integration, access to capital, supply chain resilience, and support for physical infrastructure. We would be happy to provide any more details needed upon request.
RAND Europe
Academic / research · United Kingdom · EU Transparency Register 774162031607-78
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 126 think tanks and research institutions on this site, they rank #116 by legislative files engaged — a count of participation, not a measure of influence.
- Register category
- Think tanks and research institutions
- Registered as
- RAND Europe (EU) AISBL
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track RAND in PolicySpeak: request access →
Work at RAND Europe? so we know who speaks for it.
Their record over time
RAND Europe filed 1 position on 10 Jun 2025, across 1 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from RAND Europe’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.